RU94028671A - Инсулиновый препарат, способ получения препарата, способ лечения сахарного диабета - Google Patents
Инсулиновый препарат, способ получения препарата, способ лечения сахарного диабетаInfo
- Publication number
- RU94028671A RU94028671A RU94028671/14A RU94028671A RU94028671A RU 94028671 A RU94028671 A RU 94028671A RU 94028671/14 A RU94028671/14 A RU 94028671/14A RU 94028671 A RU94028671 A RU 94028671A RU 94028671 A RU94028671 A RU 94028671A
- Authority
- RU
- Russia
- Prior art keywords
- zinc
- drug
- insulin
- producing
- drug according
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims 12
- 239000003814 drug Substances 0.000 title claims 7
- 229940079593 drugs Drugs 0.000 title claims 7
- 108090001061 Insulin Proteins 0.000 title claims 6
- 102000004877 Insulin Human genes 0.000 title claims 6
- 206010012601 Diabetes mellitus Diseases 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940091251 Zinc Supplements Drugs 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- LEMUFSYUPGXXCM-JNEQYSBXSA-N Caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 claims 2
- 108010061168 Ultralente Insulin Proteins 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 229960000314 Zinc Acetate Drugs 0.000 claims 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 claims 1
- VNDYJBBGRKZCSX-UHFFFAOYSA-L Zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 1
- BHHYHSUAOQUXJK-UHFFFAOYSA-L Zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 claims 1
- UAYWVJHJZHQCIE-UHFFFAOYSA-L Zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 230000002335 preservative Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
- 239000004246 zinc acetate Substances 0.000 claims 1
- 229940102001 zinc bromide Drugs 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 229960001939 zinc chloride Drugs 0.000 claims 1
- 229960001763 zinc sulfate Drugs 0.000 claims 1
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 1
Claims (9)
1. Препарат инсулина человека, содержащий суспензию кристаллов инсулина Ultralente с общим содержанием цинка в препарате от около 0,5 до около 20 мг на 100 единиц инсулина.
2. Препарат по п. 1, отличающийся тем, что он дополнительно содержит консерванты.
3. Препарат по п. 2, отличающийся тем, что он дополнительно содержит агенты, сохраняющие изотоничность.
4. Препарат по п. 3, отличающийся тем, что он дополнительно содержит буфер.
5. Препарат по п. 4, отличающийся тем, что общая концентрация цинка в препарате от около 0,5 до около 7 мг на 100 единиц инсулина.
6. Способ получения препарата инсулина по одному из пп. 1 - 5, отличающийся тем, что он включает объединение цинка с кристаллами инсулина Ultralente.
7. Способ по п. 6, отличающийся тем, что применяемый цинк является солью цинка, которую выбирают из группы, включающей ацетат цинка, бромид цинка, хлорид цинка, йодид цинка, фторид цинка и сульфат цинка.
8. Способ лечения сахарного диабета у пациентов-людей, отличающийся тем, что он включает введение указанным пациентам терапевтически приемлемого количества препарата инсулина по любому из пп. 1 - 5 путем подкожной инъекции.
9. Способ по п. 8, отличающийся тем, что указанную подкожную инъекцию назначают один раз в день.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/106,106 US5534488A (en) | 1993-08-13 | 1993-08-13 | Insulin formulation |
| US08/106106 | 1993-08-13 | ||
| US08/106,106 | 1993-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU94028671A true RU94028671A (ru) | 1997-11-10 |
| RU2135205C1 RU2135205C1 (ru) | 1999-08-27 |
Family
ID=22309529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU94028671A RU2135205C1 (ru) | 1993-08-13 | 1994-08-09 | Инсулиновый препарат, способ получения препарата, способ лечения сахарного диабета |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5534488A (ru) |
| EP (1) | EP0646379B1 (ru) |
| JP (1) | JPH07149660A (ru) |
| KR (1) | KR950005324A (ru) |
| CN (1) | CN1109364A (ru) |
| AT (1) | ATE207761T1 (ru) |
| AU (1) | AU674975B2 (ru) |
| BR (1) | BR9403204A (ru) |
| CA (1) | CA2129763A1 (ru) |
| CO (1) | CO4230235A1 (ru) |
| CZ (1) | CZ193794A3 (ru) |
| DE (1) | DE69428860T2 (ru) |
| DK (1) | DK0646379T3 (ru) |
| ES (1) | ES2164691T3 (ru) |
| HU (1) | HUT67853A (ru) |
| IL (1) | IL110581A0 (ru) |
| NO (1) | NO942959L (ru) |
| NZ (1) | NZ264197A (ru) |
| PE (1) | PE14495A1 (ru) |
| PH (1) | PH30757A (ru) |
| PL (1) | PL177002B1 (ru) |
| PT (1) | PT646379E (ru) |
| RU (1) | RU2135205C1 (ru) |
| TW (1) | TW326394B (ru) |
| UA (1) | UA27874C2 (ru) |
| YU (1) | YU50494A (ru) |
| ZA (1) | ZA945939B (ru) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578238A (en) * | 1992-10-30 | 1996-11-26 | Lord Corporation | Magnetorheological materials utilizing surface-modified particles |
| YU18596A (sh) * | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| EP1396272A1 (en) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Insoluble Insulin Compositions for Controlling Blood Glucose |
| US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| EP1196446A1 (en) * | 1999-06-29 | 2002-04-17 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| ATE328605T1 (de) * | 2000-03-24 | 2006-06-15 | Genentech Inc | Verwendung von insulin zur behandlung von knorpelkrankheiten |
| US6743371B2 (en) | 2000-10-06 | 2004-06-01 | The Adviser-Defence Research & Development Organisation Ministry Of Defence, Government Of India | Magneto sensitive fluid composition and a process for preparation thereof |
| US6875368B2 (en) * | 2000-11-29 | 2005-04-05 | The Adviser Defence Research And Development Organisation, Ministry Of Defence, Government Of India | Magnetorheological fluid composition and a process for preparation thereof |
| DE60217066D1 (de) * | 2001-02-09 | 2007-02-08 | Genentech Inc | Kristallisierung von igf-1 |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| EP2272501B1 (en) | 2002-01-09 | 2013-03-20 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| WO2005072803A1 (en) * | 2004-01-16 | 2005-08-11 | Biodel, Inc. | Sublingual drug delivery device |
| EP1740154B1 (en) * | 2004-03-12 | 2009-06-17 | Biodel, Inc. | Insulin compositions with improved absorption |
| US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US20080085298A1 (en) * | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
| AU2005240213B8 (en) | 2004-05-06 | 2011-10-20 | Emisphere Technologies, Inc. | Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate |
| EP1745004B8 (en) * | 2004-05-14 | 2016-07-27 | Emisphere Technologies, Inc. | Aryl ketone compounds and compositions for delivering active agents |
| RU2527893C2 (ru) | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| AU2005271526B2 (en) * | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| JP2008509933A (ja) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| CA2649109A1 (en) * | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| PL2134351T3 (pl) | 2007-03-13 | 2017-10-31 | Jds Therapeutics Llc | Sposoby i kompozycje do przedłużonego uwalniania chromu |
| WO2008124522A2 (en) * | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| WO2009050738A2 (en) | 2007-10-16 | 2009-04-23 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
| MX2010007342A (es) * | 2008-01-04 | 2010-08-26 | Biodel Inc | Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. |
| ES2772731T3 (es) | 2008-10-17 | 2020-07-08 | Sanofi Aventis Deutschland | Combinación de una insulina y un agonista de GLP-1 |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| PE20121316A1 (es) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina |
| EP2554183B1 (de) | 2009-11-13 | 2018-04-04 | Sanofi-Aventis Deutschland GmbH | Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten, ein Insulin und Methionin |
| EP2538966A4 (en) * | 2010-02-22 | 2014-02-19 | Univ Case Western Reserve | ANALOGUE PREPARATIONS OF INSULIN WITH EXTENDED ACTION IN SOLUBLE AND CRYSTALLINE FORMS |
| RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
| KR101836957B1 (ko) | 2011-03-01 | 2018-03-09 | 제이디에스 테라퓨틱스, 엘엘씨 | 당뇨병, 저혈당 및 관련 장애를 치료 및 예방하기 위한 인슐린과 크롬을 포함하는 조성물 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2017139337A1 (en) | 2016-02-11 | 2017-08-17 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
| US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
| US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
| US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
| US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
| US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
| US2799622A (en) * | 1953-11-14 | 1957-07-16 | Novo Terapeutisk Labor As | Process of producing insulin crystals of substantially uniform size and compositions thereof |
| US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
| DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
-
1993
- 1993-08-13 US US08/106,106 patent/US5534488A/en not_active Expired - Fee Related
-
1994
- 1994-08-04 HU HU9402287A patent/HUT67853A/hu unknown
- 1994-08-08 NZ NZ264197A patent/NZ264197A/en unknown
- 1994-08-08 ZA ZA945939A patent/ZA945939B/xx unknown
- 1994-08-08 IL IL11058194A patent/IL110581A0/xx not_active IP Right Cessation
- 1994-08-08 BR BR9403204A patent/BR9403204A/pt not_active Application Discontinuation
- 1994-08-08 PE PE1994248043A patent/PE14495A1/es not_active Application Discontinuation
- 1994-08-09 DK DK94305883T patent/DK0646379T3/da active
- 1994-08-09 EP EP94305883A patent/EP0646379B1/en not_active Expired - Lifetime
- 1994-08-09 NO NO942959A patent/NO942959L/no not_active Application Discontinuation
- 1994-08-09 KR KR1019940019550A patent/KR950005324A/ko active IP Right Grant
- 1994-08-09 TW TW083107259A patent/TW326394B/zh active
- 1994-08-09 UA UA94085696A patent/UA27874C2/uk unknown
- 1994-08-09 CA CA002129763A patent/CA2129763A1/en not_active Abandoned
- 1994-08-09 AT AT94305883T patent/ATE207761T1/de not_active IP Right Cessation
- 1994-08-09 RU RU94028671A patent/RU2135205C1/ru active
- 1994-08-09 CO CO94035010A patent/CO4230235A1/es unknown
- 1994-08-09 PL PL94304600A patent/PL177002B1/pl unknown
- 1994-08-09 PH PH48764A patent/PH30757A/en unknown
- 1994-08-09 PT PT94305883T patent/PT646379E/pt unknown
- 1994-08-09 ES ES94305883T patent/ES2164691T3/es not_active Expired - Lifetime
- 1994-08-09 DE DE69428860T patent/DE69428860T2/de not_active Expired - Fee Related
- 1994-08-10 YU YU50494A patent/YU50494A/sh unknown
- 1994-08-10 JP JP6188204A patent/JPH07149660A/ja not_active Withdrawn
- 1994-08-10 CZ CZ941937A patent/CZ193794A3/cs unknown
- 1994-08-10 CN CN94109082A patent/CN1109364A/zh active Pending
- 1994-08-12 AU AU70247/94A patent/AU674975B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU94028671A (ru) | Инсулиновый препарат, способ получения препарата, способ лечения сахарного диабета | |
| AU641721B2 (en) | Insulin preparations containing nicotinic acid or nicotinamide | |
| CA2151560C (en) | Insulin analog formulations | |
| DE19521753B4 (de) | Monomere Insulinanalogonformulierungen | |
| US3917824A (en) | Pharmaceutical compositions containing epidermal growth factor or closely related derivatives thereof for inhibiting the secretion of acidic gastric juice in warm blooded animals | |
| US20070155654A1 (en) | Novel formulations | |
| US5177058A (en) | Pharmaceutical formulation for the treatment of diabetes mellitus | |
| CA2285203A1 (en) | Compositions containing capsaicin or capsaicin analogues and a local anesthetic | |
| EP0921812B2 (en) | Insulin preparations containing a halogenide | |
| HUP0300642A2 (hu) | Antidiabetikus készítmény és alkalmazása | |
| Hildebrandt et al. | The subcutaneous absorption of human and bovine ultralente insulin formulations | |
| Chung et al. | Effect of Kp, an antitumor protein-polysaccharide from mycelial culture of Phellinus linteus on the humoral immune response of tumor-bearing ICR mice to sheep red blood cells | |
| EP0265214A2 (en) | Polypeptide preparation | |
| Slobody et al. | Effect of severe hypoxia on blood-cerebrospinal fluid barrier | |
| Lee et al. | The effects of magnesium sulfate infusion on blood pressure and vascular responsiveness during pregnancy | |
| SE9201584D0 (sv) | Use of alpha-ketoglutarate | |
| RU2003113987A (ru) | Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны | |
| RU95112520A (ru) | Применение 4'-йодо-4'-деоксидоксорубицина для лечения амилоидоза, способ лечения амилоидоза | |
| Veyssier et al. | Concentrations of moxalactam in ventricular CSF during the treatment of a Klebsiella pneumoniae. | |
| RU93042330A (ru) | Способ получения глазных капель пилокарпина гидрохлорида пролонгированного действия | |
| Berigan et al. | Therapeutic lithium-related cardiac conduction disturbance in a previously healthy patient: a case report | |
| Chiba et al. | Effect of endotoxin on the SA node in situ in the dog heart | |
| JPH10203961A (ja) | 糖尿病患者用電解質輸液剤 | |
| RU96115219A (ru) | Способ лечения больных сахарным диабетом | |
| 徐济民 et al. | ANTIARRHYTHMIC ACTION OF CHANGROLIN ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION |